Natera Revenue Grows 40% Driven by Signatera Adoption

Natera reported revenue growth of 40% year-over-year in the second quarter of 2025. This increase resulted from higher clinical adoption of its Signatera testing platform and an expansion of its commercial sales force. The company is moving from niche utilization toward broader clinical integration while managing R&D investments alongside revenue recognition trends.

"What we’re seeing in terms of the adoption of the product is much more generalized adoption in the clinic, where it used to be very rifle shot," said Mike, an executive at Natera, during the 2026 Global Healthcare Conference.

Scaling Operations and Clinical Reach

Growth stems from the uptake of the Signatera test. According to a transcript of the 2026 Global Healthcare Conference, sequential unit growth for the test reached 34,000 in the second quarter of 2025, compared to 25,000 in the first quarter of that year.

To support this demand, Natera increased its commercial sales team from 150 to over 300 representatives. The company completed most of these hires during the first half of 2025 to increase its presence within oncology clinics.

Revenue Recognition and Pricing Dynamics

As the company expands, it is refining its accounting for collections. Executives noted that historical accruals are being surpassed by actual payment receipts, resulting in true-ups that reflect higher revenue realization.

"I think that over time the true-ups just kind of turn into ASP because what that represents is like, hey, we are collecting above where we had accrued historically," the Natera executive said.

Market Position and Financial Context

Natera (NTRA) traded at $369.39 on September 18, 2026. The company is focused on maintaining its growth trajectory while managing research and development spending for its diagnostic pipeline. The shift from targeted usage to generalized clinical adoption indicates a change in how oncologists integrate molecular residual disease testing into patient care workflows.